Skip to main
FBRX

Forte Biosciences (FBRX) Stock Forecast & Price Target

Forte Biosciences (FBRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Forte Biosciences Inc. is progressing in preclinical trials with its proprietary therapeutic molecule, FB-102, which is positioned to address multiple autoimmune conditions, tapping into a largely untapped market potential. The increasing R&D expenses suggest a strong commitment to advancing its clinical and manufacturing capabilities, which is a positive sign for future product development. Additionally, market analyses indicate that competitive therapies exhibit significant growth, suggesting that FB-102 could capture substantial market share as a preferred first-line therapy if adverse effects are managed carefully.

Bears say

Forte Biosciences faces significant challenges from market competition, which could hinder its ability to penetrate the market and affect pricing strategies for its product candidate FB-102. Additionally, potential delays in clinical development, regulatory approvals, and commercialization timelines could lead to prolonged development periods and increased costs, adversely impacting the company’s financial health. Furthermore, the underperformance of FB-102 in comparative study metrics suggests it may struggle against competitors, raising concerns about its efficacy in the broader marketplace.

Forte Biosciences (FBRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Forte Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Forte Biosciences (FBRX) Forecast

Analysts have given Forte Biosciences (FBRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Forte Biosciences (FBRX) has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Forte Biosciences (FBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.